WeDaita Platform BioMedAI

Target to Candidate — One Knowledge Platform

WeDaita is the knowledge platform for drug discovery. BioMedAI puts autonomous AI agents and proprietary models to work across your pipeline — helping scientists move faster and decide with greater confidence.

Try BioMedAI Full AI platform Book a Call 30-min consultation
  See It in Action
200+MCP Tools
40+Databases
GraphRAGReasoning
Proprietary AI Models
CLINAVA clinical progression
GENAVA virtual target validation
Integrated Platform

Prediction-Driven Drug Discovery.

From target selection to patient advancement — guided by clinical progression intelligence at every stage.

Three specialized agent systems, each designed to reduce attrition at its stage and feed higher-confidence decisions into the next.

Stage 1 — Target Discovery
TDIA
Target Discovery Intelligence Agents
6 Agents Live
Target selection and prioritization, helping researchers identify and evaluate high-potential drug targets by integrating evidence from both public and proprietary data sources and generating predictions using our virtual AI models.
  • Deep Research Assistant
  • Disease Hypothesis Generation
  • Drug Target Prioritization
  • Drug Repurposing
  • Competitive Landscape
  • Biomarker Discovery
Focus
Target Discovery
Stage 2 — Drug Design
DDIA
Drug Design Intelligence Agents
1 Agent Live
Bridges the translation gap by automating protein, antibody, and small molecule design — with clinical progression guardrails baked into the generative process to reduce preclinical failure rates.
  • Protein / antibody drug design
  • Peptide/MacrocycleIn Dev
  • Small molecule design & optimisationIn Dev
Focus
AI Drug Design
Stage 3 — Clinical Trials
CTIA
Clinical Trial Intelligence Agents
1 Agent Live
Forecasts drug progression and addresses late-stage attrition through digital simulations, predictive recruitment, and biomarker-driven patient stratification — moving candidates from the lab ultimately to patients.
  • Pharmacovigilance
  • Predictive patient recruitmentRoadmap
  • AI-assisted protocol designRoadmap
  • Portfolio optimizationRoadmap
  • Digital twin trial simulationRoadmap
Focus
Clinical Prediction

See BioMedAI in Action

See how BioMedAI DBRA agents deliver trusted biomedical insights through intelligent AI agents

  • Plug-and-play biomedical AI via WeDaita MCP services
  • High-confidence insights from verified medical and clinical databases
  • Rapid literature review and clinical trial intelligence
  • Seamless agent-tool integration with zero local installation
AI RESEARCH INTELLIGENCE

Research Digest

AI-curated papers, FDA approvals, clinical compounds, and disclosures from drug discovery's leading sources — scored for relevance by the WeDaita AI agent every week.

Explore Research Digest
Target Identification
GWAS associations, CRISPR screen hits, druggability assessments
Peer-reviewed evidence and industry pipeline news on novel drug targets, scored for translational relevance.
Drug Design
FDA approvals, clinical compounds, molecular disclosures, patents
AI molecular generation, openFDA NDA approvals, ChEMBL Phase I–III candidates, and Drug Hunter patent roundups.
Clinical Trials
Active trials, regulatory milestones, trial methodology
ClinicalTrials.gov updates, FDA and EMA designations, IND filings, and patient stratification research.
3Topics
WeeklyUpdates
WeDaita AIRelevance Scoring
6+Data Sources
Latest from WeDaita

News & Blog

Company updates, tutorials, and community posts — all in one place.

Stay Ahead

AI Drug Discovery, Delivered Monthly

Get curated insights on AI-driven target identification, therapeutic design, and BioMedAI platform updates — directly to your inbox.

No spam. Unsubscribe at any time. We respect your privacy.

Built by People Who've Lived the Problem

The Team Behind BioMedAI

Scientists, engineers, and domain experts united by one mission — making drug discovery faster and smarter.

Wenliang Zhang
Wenliang Zhang, PhD, MMed
Founder, CEO/CTO
  • Director of Data Science: Pfizer, Exo Therapeutics
  • Principal Data Engineer: AbbVie
  • Principal Software Engineer: PerkinElmer, Akoya Bio
  • Computational Biologist: Bluebird Bio, Tesaro
Chao Yang
Chao Yang, PhD
AI/ML Computational Chemistry Advisor
  • PhD in Chemistry, New York University
  • Postdoc Research, The Rockefeller University
  • Computational Chemistry: Axle Informatics, Exo Therapeutics
  • AI-guided Virtual Screening and Drug Design
Elena Chernokalskaya
Elena Chernokalskaya, Ph.D
Mentor and Growth Advisor
  • Founder, Boston Business Mentor
  • Certified Counselor, SCORE Mentors
  • Scientific Advisory Board, 908 Devices
  • Executive, Cytiva & GE Helathcare
  • Proteomics Group Leader, Vertex Pharmaceuticals
All Members  
The Validation

Ecosystem Recognition & Strategic Support

Selected by leading innovation programs supporting AI and life sciences.

NVIDIA Inception Program

Member of NVIDIA’s global startup program accelerating AI innovation — providing access to the NVIDIA AI ecosystem, technical resources, and industry connections.

awsActivate

Qualified for AWS startup support, cloud credits, and infrastructure resources to accelerate scalable AI platform development.

Harvard Business School Foundry

Selected for entrepreneurial support and founder ecosystem access through Harvard Business School’s innovation programs.

Grounded in Primary Scientific Sources

Every insight traces back to 41 primary databases (PubMed, UniProt, ChEMBL, PDB, and more) and 173 scientific tools — not black-box outputs.

Built by Drug Discovery Scientists

Our team has decades of combined experience in computational biology, medicinal chemistry, and AI research.

Researcher in the Loop, Always

BioMedAI accelerates your thinking — your scientific judgement drives every key decision.

Ready to Accelerate Your Drug Discovery?

BioMedAI is live — start with target identification and protein drug design today, with more modules launching soon.

  Try BioMedAI   Book a Demo